Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

IGFBP7 is not required for B-RAF-induced melanocyte senescence.

Scurr LL, Pupo GM, Becker TM, Lai K, Schrama D, Haferkamp S, Irvine M, Scolyer RA, Mann GJ, Becker JC, Kefford RF, Rizos H.

Cell. 2010 May 14;141(4):717-27. doi: 10.1016/j.cell.2010.04.021.

2.
3.

Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.

Yeh AH, Bohula EA, Macaulay VM.

Oncogene. 2006 Oct 26;25(50):6574-81. Epub 2006 May 22.

PMID:
16715137
4.

Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7.

Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR.

Cell. 2008 Feb 8;132(3):363-74. doi: 10.1016/j.cell.2007.12.032.

5.

Monitoring oncogenic B-RAF-induced senescence in melanocytes.

Tran SL, Rizos H.

Methods Mol Biol. 2013;965:313-26. doi: 10.1007/978-1-62703-239-1_21.

PMID:
23296668
6.

Role for IGFBP7 in senescence induction by BRAF.

Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR.

Cell. 2010 May 28;141(5):746-7. doi: 10.1016/j.cell.2010.05.014. No abstract available.

7.

Oncogene activation in melanocytes links reactive oxygen to multinucleated phenotype and senescence.

Leikam C, Hufnagel A, Schartl M, Meierjohann S.

Oncogene. 2008 Nov 27;27(56):7070-82. doi: 10.1038/onc.2008.323. Epub 2008 Sep 22.

PMID:
18806824
8.

The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.

Babchia N, Calipel A, Mouriaux F, Faussat AM, Mascarelli F.

Invest Ophthalmol Vis Sci. 2010 Jan;51(1):421-9. doi: 10.1167/iovs.09-3974. Epub 2009 Aug 6.

PMID:
19661225
9.

Oncogenic BRAF-positive dysplastic nevi and the tumor suppressor IGFBP7--challenging the concept of dysplastic nevi as precursor lesions?

Decarlo K, Yang S, Emley A, Wajapeyee N, Green M, Mahalingam M.

Hum Pathol. 2010 Jun;41(6):886-94. doi: 10.1016/j.humpath.2009.12.002. Epub 2010 Mar 16.

PMID:
20233623
10.

Oncogenic B-Raf(V600E) induces spindle abnormalities, supernumerary centrosomes, and aneuploidy in human melanocytic cells.

Cui Y, Borysova MK, Johnson JO, Guadagno TM.

Cancer Res. 2010 Jan 15;70(2):675-84. doi: 10.1158/0008-5472.CAN-09-1491. Epub 2010 Jan 12.

11.

Oncogenic Braf induces melanocyte senescence and melanoma in mice.

Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K, Delmas V, Larue L, Pritchard C, Marais R.

Cancer Cell. 2009 Apr 7;15(4):294-303. doi: 10.1016/j.ccr.2009.02.022.

12.

B-RAF is a therapeutic target in melanoma.

Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, Ogilvie L, Hedley D, Martin J, Marshall CJ, Springer CJ, Marais R.

Oncogene. 2004 Aug 19;23(37):6292-8.

PMID:
15208680
13.

Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.

Vredeveld LC, Possik PA, Smit MA, Meissl K, Michaloglou C, Horlings HM, Ajouaou A, Kortman PC, Dankort D, McMahon M, Mooi WJ, Peeper DS.

Genes Dev. 2012 May 15;26(10):1055-69. doi: 10.1101/gad.187252.112. Epub 2012 May 1.

14.

BRAFE600-associated senescence-like cell cycle arrest of human naevi.

Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi WJ, Peeper DS.

Nature. 2005 Aug 4;436(7051):720-4.

15.

p16/cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis, and immortalization: possible implications for melanoma progression.

Sviderskaya EV, Gray-Schopfer VC, Hill SP, Smit NP, Evans-Whipp TJ, Bond J, Hill L, Bataille V, Peters G, Kipling D, Wynford-Thomas D, Bennett DC.

J Natl Cancer Inst. 2003 May 21;95(10):723-32.

PMID:
12759390
16.

Adhesion-dependent activation of the ERK1/2 cascade is by-passed in melanoma cells.

Conner SR, Scott G, Aplin AE.

J Biol Chem. 2003 Sep 5;278(36):34548-54. Epub 2003 Jun 23.

17.

Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.

Boyd AS, Shakhtour B, Shyr Y.

J Am Acad Dermatol. 2008 May;58(5):750-4. doi: 10.1016/j.jaad.2007.12.026. Epub 2008 Feb 4.

PMID:
18249467
18.

Proliferation arrest in B-Raf mutant melanoma cell lines upon MAPK pathway activation.

Houben R, Ortmann S, Drasche A, Troppmair J, Herold MJ, Becker JC.

J Invest Dermatol. 2009 Feb;129(2):406-14. doi: 10.1038/jid.2008.214. Epub 2008 Jul 24.

19.

Oncogenic B-RAF(V600E) signaling induces the T-Box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion.

Boyd SC, Mijatov B, Pupo GM, Tran SL, Gowrishankar K, Shaw HM, Goding CR, Scolyer RA, Mann GJ, Kefford RF, Rizos H, Becker TM.

J Invest Dermatol. 2013 May;133(5):1269-77. doi: 10.1038/jid.2012.421. Epub 2012 Nov 29.

20.

The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes.

Yu H, McDaid R, Lee J, Possik P, Li L, Kumar SM, Elder DE, Van Belle P, Gimotty P, Guerra M, Hammond R, Nathanson KL, Dalla Palma M, Herlyn M, Xu X.

Am J Pathol. 2009 Jun;174(6):2367-77. doi: 10.2353/ajpath.2009.081057. Epub 2009 Apr 23.

Supplemental Content

Support Center